144 related articles for article (PubMed ID: 21329956)
1. Papillomavirus capsid proteins mutually impact structure.
Chen HS; Conway MJ; Christensen ND; Alam S; Meyers C
Virology; 2011 Apr; 412(2):378-83. PubMed ID: 21329956
[TBL] [Abstract][Full Text] [Related]
2. Study of infectious virus production from HPV18/16 capsid chimeras.
Chen HS; Bromberg-White J; Conway MJ; Alam S; Meyers C
Virology; 2010 Sep; 405(2):289-99. PubMed ID: 20598725
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
[TBL] [Abstract][Full Text] [Related]
4. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
[TBL] [Abstract][Full Text] [Related]
5. Mutations in human papillomavirus type 16 L1 hypervariable surface-exposed loops affect L2 binding and DNA encapsidation.
Faust H; Dillner J
J Gen Virol; 2013 Aug; 94(Pt 8):1841-1849. PubMed ID: 23658208
[TBL] [Abstract][Full Text] [Related]
6. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
[TBL] [Abstract][Full Text] [Related]
7. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
[TBL] [Abstract][Full Text] [Related]
8. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
Jagu S; Karanam B; Gambhira R; Chivukula SV; Chaganti RJ; Lowy DR; Schiller JT; Roden RB
J Natl Cancer Inst; 2009 Jun; 101(11):782-92. PubMed ID: 19470949
[TBL] [Abstract][Full Text] [Related]
9. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine.
Gu Y; Wei M; Wang D; Li Z; Xie M; Pan H; Wu T; Zhang J; Li S; Xia N
Vaccine; 2017 Aug; 35(35 Pt B):4637-4645. PubMed ID: 28736197
[TBL] [Abstract][Full Text] [Related]
10. Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17-36.
Bywaters SM; Brendle SA; Tossi KP; Biryukov J; Meyers C; Christensen ND
Viruses; 2017 Nov; 9(11):. PubMed ID: 29125554
[TBL] [Abstract][Full Text] [Related]
11. Role of L2 cysteines in papillomavirus infection and neutralization.
Gambhira R; Jagu S; Karanam B; Day PM; Roden R
Virol J; 2009 Oct; 6():176. PubMed ID: 19860897
[TBL] [Abstract][Full Text] [Related]
12. Impact of naturally occurring variation in the human papillomavirus (HPV) 33 capsid proteins on recognition by vaccine-induced cross-neutralizing antibodies.
Godi A; Bissett SL; Miller E; Beddows S
J Gen Virol; 2017 Jul; 98(7):1755-1761. PubMed ID: 28691664
[TBL] [Abstract][Full Text] [Related]
13. Impact of naturally occurring variation in the human papillomavirus 52 capsid proteins on recognition by type-specific neutralising antibodies.
Godi A; Bissett SL; Masloh S; Fleury M; Li S; Zhao Q; Xia N; Cocuzza CE; Beddows S
J Gen Virol; 2019 Feb; 100(2):237-245. PubMed ID: 30657447
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic Vascular Endothelial Growth Factor-Blocking Peptides Displayed on the Capsid of an Infectious Oncolytic Parvovirus: Assembly and Immune Interactions.
Grueso E; Sánchez-Martínez C; Calvo-López T; de Miguel FJ; Blanco-Menéndez N; Fernandez-Estevez M; Elizalde M; Sanchez J; Kourani O; Martin D; Tato A; Guerra M; Andrés G; Almendral JM
J Virol; 2019 Oct; 93(19):. PubMed ID: 31315994
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies.
Day PM; Gambhira R; Roden RB; Lowy DR; Schiller JT
J Virol; 2008 May; 82(9):4638-46. PubMed ID: 18305047
[TBL] [Abstract][Full Text] [Related]
16. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.
Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP
J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908
[TBL] [Abstract][Full Text] [Related]
17. Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.
Wang JW; Jagu S; Wu WH; Viscidi RP; Macgregor-Das A; Fogel JM; Kwak K; Daayana S; Kitchener H; Stern PL; Gravitt PE; Trimble CL; Roden RB
Clin Vaccine Immunol; 2015 Jul; 22(7):806-16. PubMed ID: 25972404
[TBL] [Abstract][Full Text] [Related]
18. Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies.
Combelas N; Saussereau E; Fleury MJ; Ribeiro T; Gaitan J; Duarte-Forero DF; Coursaget P; Touzé A
J Transl Med; 2010 Mar; 8():28. PubMed ID: 20334659
[TBL] [Abstract][Full Text] [Related]
19. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.
Schellenbacher C; Roden R; Kirnbauer R
J Virol; 2009 Oct; 83(19):10085-95. PubMed ID: 19640991
[TBL] [Abstract][Full Text] [Related]
20. Comparison of human papillomavirus type 16 replication in tonsil and foreskin epithelia.
Israr M; Biryukov J; Ryndock EJ; Alam S; Meyers C
Virology; 2016 Dec; 499():82-90. PubMed ID: 27639574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
